Overexpression of ANXA1 in Penile Carcinomas Positive for High-Risk HPVs

Carregando...
Imagem de Miniatura
Citações na Scopus
19
Tipo de produção
article
Data de publicação
2013
Editora
PUBLIC LIBRARY SCIENCE
Indexadores
Título da Revista
ISSN da Revista
Título do Volume
Autores
CALMON, Marilia Freitas
MOTA, Manlio Tasso de Oliveira
BABETO, Erica
CANDIDO, Natalia Maria
GIROL, Ana Paula
MENDIBURU, Carlos Fabian
BONILHA, Jane Lopes
SILVESTRE, Rodrigo Vellasco Duarte
ROSA, Bruno Miziara
THOME, Jorge Alberto
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
PLOS ONE, v.8, n.1, article ID e53260, 7p, 2013
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
The incidence of penile cancer varies between populations but is rare in developed nations. Penile cancer is associated with a number of established risk factors and associated diseases including phimosis with chronic inflammation, human papillomavirus (HPV) infection, poor hygiene and smoking. The objective of this study was to identify genes related to this type of cancer. The detection of HPV was analyzed in 47 penile squamous cell carcinoma samples. HPV DNA was detected in 48.9% of penile squamous cell carcinoma cases. High-risk HPV were present in 42.5% of cases and low-risk HPV were detected in 10.6% of penile squamous cell carcinomas. The RaSH approach identified differential expression of Annexin A1 (ANXA1), p16, RPL6, PBEF1 and KIAA1033 in high-risk HPV positive penile carcinoma; ANXA1 and p16 were overexpressed in penile squamous cells positive for high-risk HPVs compared to normal penile samples by qPCR. ANXA1 and p16 proteins were significantly more expressed in the cells from high-risk HPV-positive penile carcinoma as compared to HPV-negative tumors (p<0.0001) independently of the subtype of the carcinoma. Overexpression of ANXA1 might be mediated by HPV E6 in penile squamous cell carcinoma of patients with high-risk HPVs, suggesting that this gene plays an important role in penile cancer.
Palavras-chave
Referências
  1. Ahn SH, 1997, CLIN EXP METASTAS, V15, P151, DOI 10.1023/A:1018452810915
  2. Alldridge LC, 1999, J BIOL CHEM, V274, P37620, DOI 10.1074/jbc.274.53.37620
  3. Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389
  4. [Armed Forces Institute of Pathology (U.S.) National Research Council (U.S.)], ATLAS TUMOR PATHOLOG
  5. Backes DM, 2009, CANCER CAUSE CONTROL, V20, P449, DOI 10.1007/s10552-008-9276-9
  6. Bai XF, 2004, WORLD J GASTROENTERO, V10, P1466
  7. Barnholtz-Sloan JS, 2007, UROL ONCOL-SEMIN ORI, V25, P361, DOI 10.1016/j.urolonc.2006.08.029
  8. Begum S, 2007, CLIN CANCER RES, V13, P1186, DOI 10.1158/1078-0432.CCR-06-1690
  9. Bleeker MCG, 2009, WORLD J UROL, V27, P141, DOI 10.1007/s00345-008-0302-z
  10. Calmon MF, 2009, NEOPLASIA, V11, P1329, DOI 10.1593/neo.91110
  11. Calmon MF, 2011, THESCIENTIFICWORLDJO, V11, P269, DOI 10.1100/tsw.2011.24
  12. Cubilla AL, 2011, AM J SURG PATHOL, V35, P253, DOI 10.1097/PAS.0b013e318203cdba
  13. HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057
  14. de Coupade C, 2000, HEPATOLOGY, V31, P371, DOI 10.1002/hep.510310217
  15. Dorovkov MV, 2004, J BIOL CHEM, V279, P50643, DOI 10.1074/jbc.C400441200
  16. Edge SB, 2010, AJCC CANC STAGING MA
  17. Favorito LA, 2008, INT BRAZ J UROL, V34, P587, DOI 10.1590/S1677-55382008000500007
  18. Ferrandiz-Pulido C, 2012, J AM ACAD DERMATOL
  19. Ferreux E, 2003, J PATHOL, V201, P109, DOI 10.1002/path.1394
  20. Fregonesi PAG, 2003, J HISTOCHEM CYTOCHEM, V51, P1291
  21. Pedrero JMG, 2004, AM J PATHOL, V164, P73
  22. Hannon Robert, 2003, FASEB Journal, V17, P253
  23. Hippo Y, 2001, CANCER RES, V61, P889
  24. Howie HL, 2009, VIROLOGY, V384, P324, DOI 10.1016/j.virol.2008.11.017
  25. Hu N, 2004, CLIN CANCER RES, V10, P6013, DOI 10.1158/1078-0432.CCR-04-0317
  26. HUIBREGTSE JM, 1993, MOL CELL BIOL, V13, P4918
  27. JOHNSON MD, 1989, HUM PATHOL, V20, P772, DOI 10.1016/0046-8177(89)90071-3
  28. KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634
  29. Kang JS, 2002, CLIN CANCER RES, V8, P117
  30. Lu DW, 2003, MODERN PATHOL, V16, P692, DOI 10.1097/01.MP.0000077417.08371.CE
  31. Masaki T, 1996, HEPATOLOGY, V24, P72, DOI 10.1002/hep.510240114
  32. Miralles-Guri C, 2009, J CLIN PATHOL, V62, P870, DOI 10.1136/jcp.2008.063149
  33. Moody CA, 2010, NAT REV CANCER, V10, P550, DOI 10.1038/nrc2886
  34. Nam Eun Ji, 2008, J Gynecol Oncol, V19, P162, DOI 10.3802/jgo.2008.19.3.162
  35. Nam EJ, 2007, GYNECOL ONCOL, V104, P207, DOI 10.1016/j.ygyno.2006.07.043
  36. Nguyen M, 2002, J VIROL, V76, P13039, DOI 10.1128/JVI.76.24.13039-13048.2002
  37. Paschalidis N, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-33
  38. Paweletz CP, 2000, CANCER RES, V60, P6293
  39. Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
  40. Protzel C, 2011, WORLD J UROL, V29, P393, DOI 10.1007/s00345-010-0575-x
  41. Prowse DM, 2008, BRIT J DERMATOL, V158, P261, DOI 10.1111/j.1365-2133.2007.08305.x
  42. Raiol T, 2011, INTERVIROLOGY, V54, P146, DOI 10.1159/000320199
  43. Rodrigo JP, 2005, AM J RHINOL, V19, P483
  44. Senba M, 2009, ACTA VIROL, V53, P43, DOI 10.4149/av_2009_01_43
  45. Shen DJ, 2006, HUM PATHOL, V37, P1583, DOI 10.1016/j.humpath.2006.06.001
  46. Shimoji T, 2009, J CELL BIOCHEM, V106, P1123, DOI 10.1002/jcb.22096
  47. Shirakura M, 2007, J VIROL, V81, P1174, DOI 10.1128/JVI.01684-06
  48. Silistino-Souza R, 2007, INT J CANCER, V120, P2582, DOI 10.1002/ijc.22639
  49. SLEBOS RJC, 1994, P NATL ACAD SCI USA, V91, P5320, DOI 10.1073/pnas.91.12.5320
  50. Song SY, 1999, J VIROL, V73, P5887
  51. Tewari M, 2007, ASIAN J SURG, V30, P126, DOI 10.1016/S1015-9584(09)60145-7
  52. Thomas M, 2008, ONCOGENE, V27, P7018, DOI 10.1038/onc.2008.351
  53. Villota C, 2012, J BIOL CHEM, V287, P21303, DOI 10.1074/jbc.M111.326694
  54. Xia SH, 2002, ONCOGENE, V21, P6641, DOI 10.1038/sj.onc.1205818
  55. Xin W, 2003, AM J PATHOL, V162, P255, DOI 10.1016/S0002-9440(10)63816-3
  56. Yi M, 2009, P NATL ACAD SCI USA, V106, P17886, DOI 10.1073/pnas.0901324106